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SUMMARY 
 
Studies with the WldS mutant mouse have shown that axon and synapse pathology in 
several models of neurodegenerative diseases are mechanistically related to injury-
induced axon degeneration (Wallerian degeneration). Crucially, an absence of 
SARM1 delays Wallerian degeneration as robustly as WldS, but their relative 
capacities to confer long-term protection against related, non-injury axonopathy 
and/or synaptopathy have not been directly compared. Whilst Sarm1 deletion or WldS 
can each rescue perinatal lethality and widespread Wallerian-like axonopathy in 
young NMNAT2-deficient mice, we now report that an absence of SARM1 enables 
these mice to survive into old age with no overt phenotype whereas those rescued by 
WldS invariantly develop a progressive neuromuscular defect in their hindlimbs from 
around 3 months of age. We therefore propose Sarm1 deletion as a more reliable 
tool than WldS for investigating Wallerian-like mechanisms in disease models and 
suggest that SARM1 blockade may have greater therapeutic potential than WLDS-
related strategies. 
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INTRODUCTION 
 
WldS, a spontaneous mutant mouse allele encoding a fusion protein (WLDS) with 
nicotinamide mononucleotide adenylyltransferase (NMNAT) activity, robustly delays 
injury-induced axon and synapse degeneration (Wallerian degeneration) by locally 
substituting for loss of the endogenous NMNAT2 isoform (Mack et al., 2001; Gilley 
and Coleman, 2010; Cohen et al., 2012; Conforti et al., 2014). WldS has been the tool 
of choice for investigating the molecular basis of axon pathology in animal models of 
neurodegenerative diseases and has revealed an involvement of Wallerian-like 
mechanisms in several cases (Conforti et al., 2014). Key steps in this process are 
thus potential targets for intervention in patients. 
 Sterile alpha and TIR motif-containing protein 1 (SARM1) acts downstream of 
NMNAT2 loss to promote axon degeneration (Osterloh et al., 2012; Gerdts et al., 
2013; Gilley et al., 2015; Loreto et al., 2015; Walker et al., 2017). Depletion of 
SARM1 is, to date, the only other manipulation that can delay Wallerian degeneration 
and related axon degeneration in mice as robustly as exogenous expression of 
WLDS or other NMNAT variants (Conforti et al., 2014), but its effectiveness in 
maintaining long-term health of axons and synapses in mouse models of axonopathy 
and/or synaptopathy has not yet been directly compared to WldS. Such a comparison 
is needed to ascertain the relative usefulness of Sarm1 deletion in determining 
whether Wallerian-like mechanisms are involved in models of neurodegeneration and 
should also be informative in terms of therapeutic strategies for those disorders. 
 An absence of NMNAT2 in mice causes widespread axon truncation during 
embryogenesis and perinatal lethality (Gilley et al., 2013). Interestingly, early rescue 
by WldS (dose-dependently) or by Sarm1 deletion has shown that outgrowth of 
NMNAT2-deficient axons stalls due to a Wallerian-like degenerative mechanism 
(Gilley et al., 2013; Gilley et al., 2015). Reduced NMNAT2 levels have already been 
linked to tauopathy in mice and to decreased cognitive function in humans 
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(Ljungberg et al., 2012; Ali et al., 2016), but the severity of the phenotype in mice 
lacking NMNAT2 suggests a complete lack of the protein is unlikely to directly model 
any neurodegenerative conditions. Nevertheless, these mice do represent a well-
defined and robust system for comparing the longer-term protective effects of WldS 
and Sarm1 deletion against a severe Wallerian-like axonopathy. Whilst the survival 
of NMNAT2-deficient mice homozygous either for WldS or a Sarm1 knockout allele 
up to 3 months of age with no overt problems initially suggested similarly robust 
rescue in each case (Gilley et al., 2013; Gilley et al., 2015), we now report striking 
age-dependent differences between the two lines which are likely to have important 
experimental and therapeutic implications. 
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RESULTS 
 
Locomotor defects and muscle atrophy in Nmnat2gtE/gtE;WldS/S mice, but not 
Nmnat2gtE/gtE;Sarm1-/- mice 
Mice homozygous for the Nmnat2gtE gene trap allele, lacking NMNAT2, that are 
additionally homozygous for WldS or a Sarm1 knockout allele (Nmnat2gtE/gtE;WldS/S or 
Nmnat2gtE/gtE;Sarm1-/- mice respectively) are born at the expected frequencies and 
are outwardly indistinguishable from NMNAT2-expressing littermates up to three 
months of age (Gilley et al., 2013; Gilley et al., 2015) (Table S1). However, despite 
continued silencing of the trapped Nmnat2 alleles in each case (Fig. S1A), further 
aging has revealed clear differences between the lines: Nmnat2gtE/gtE;Sarm1-/- mice 
remarkably survived for up to 2 years with no noticeable behavioral deficiency or 
phenotype, whereas Nmnat2gtE/gtE;WldS/S mice invariantly developed a conspicuous, 
progressive hindlimb defect from around 3-5 months of age. 
  The defect in Nmnat2gtE/gtE;WldS/S mice (male and female) first presented as a 
modest hindlimb gait abnormality during spontaneous locomotion, but this 
progressively deteriorated resulting in mice invariantly dragging their hindlimbs 
regularly during locomotion from around 6 months onwards as a result of worsening 
paraparesis (Movies 1-4). Consistent with this, locomotor ability of 
Nmnat2gtE/gtE;WldS/S mice in an accelerating Rotarod task deteriorated rapidly 
between 4 and 6 months (Fig. 1A). Movement became so limited by 10-12 months 
that it impaired free access to food and water so Nmnat2gtE/gtE;WldS/S mice were not 
aged further. In contrast, locomotor performance of Nmnat2gtE/gtE;Sarm1-/- mice did 
not decline during the same period (Fig. 1A and Movies 5 and 6) and 
Nmnat2gtE/gtE;Sarm1-/- mice still performed as well as Sarm1-/- controls up to at least 
15 months (Fig. 1B). 
 Deteriorating locomotor function in Nmnat2gtE/gtE;WldS/S mice coincided with 
progressive and widespread wasting of hindlimb muscles (Fig. S1B). A specific 
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analysis of gastrocnemius muscle revealed evidence of some muscle fiber atrophy 
and slightly reduced muscle weight even at 10 weeks in Nmnat2gtE/gtE;WldS/S mice, 
prior to the onset of overt locomotor dysfunction, but this had progressed to severe 
muscle fiber atrophy and loss of mass by 10 months (Fig. 1C and 1D). In contrast, no 
muscle fiber atrophy or loss of mass was seen in Nmnat2gtE/gtE;Sarm1-/- 
gastrocnemius up to 24 months (Fig. 1C-E). 
 Interestingly, although Nmnat2gtE/gtE;WldS/S mice did not lose body weight 
between 10 weeks and 10-12 months, they did fail to gain weight as expected (Fig. 
S1C). This presumably reflected loss of muscle mass in the hindlimb being broadly 
matched by normal weight gain in the upper torso and forelimbs, which appeared 
largely unaffected. In contrast, developmental weight gain in Nmnat2gtE/gtE;Sarm1-/- 
mice was comparable to Sarm1-/- controls up to 24 months (Fig. S1D).  
 
Neuromuscular denervation in Nmnat2gtE/gtE;WldS/S mice, but not 
Nmnat2gtE/gtE;Sarm1-/- mice 
Changes in neuromuscular junction (NMJ) innervation indicated that the muscle 
defect in Nmnat2gtE/gtE;WldS/S mice is neurogenic. Motor endplate occupancy in 
Nmnat2gtE/gtE;WldS/S gastrocnemius was found to be already moderately reduced at 
10 weeks, but, consistent with the timing of gastrocnemius muscle fiber atrophy and 
weight loss in these mice, by 10 months denervation was extensive with only around 
10 per cent of endplates showing normal innervation (Fig. 2A and 2B). 
 We also investigated motor endplate occupancy in a more distal hindlimb 
muscle, flexor digitorum brevis (FDB), at 10 months. Whilst muscle denervation was 
also evident in this muscle (Fig. 3A), it was actually less severe than in 
gastrocnemius at the same age. Interestingly, clear regional variation in the pattern 
of endplate occupancy was seen in FDB with discrete zones of normal innervation 
being found adjacent to zones of complete denervation (Fig. 3B and 3C). Isometric 
tension recordings indicated that this distinctive pattern of NMJ innervation reflects 
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discrete loss of entire motor units (Fig. 3D and 3E) with apparently normal function of 
remaining motor units (Fig. S2). 
 In contrast, and consistent with the lack of any locomotor problems, no 
significant endplate denervation and/or motor unit loss was evident in either 
gastrocnemius or FDB muscles from 10-month-old Nmnat2gtE/gtE;Sarm1-/- mice (Fig. 
2, Fig. 3A, 3D and 3E, and Fig. S2) and innervation remained comparable to Sarm1-/- 
controls at 24 months, despite modest age-dependent denervation in both (Fig. 2A). 
 Importantly, WldS/S and Sarm1-/- mice both performed maximally in locomotor 
tests and neither showed any signs of neuromuscular denervation at the ages 
studied. Although a direct comparison with wild-type mice will be needed to establish 
if more subtle differences in motor function exist in either line, our data suggest that 
both have broadly normal neuromuscular function. The defect in Nmnat2gtE/gtE;WldS/S 
mice thus appears to be specific to a declining inability of WLDS to counter the lack of 
NMNAT2 in older mice rather than other intrinsic differences. 
 
No loss of myelinated tibial nerve axons in either Nmnat2gtE/gtE;WldS/S or 
Nmnat2gtE/gtE;Sarm1-/- mice 
Despite progressive denervation of motor endplates in hindlimb muscles from 
Nmnat2gtE/gtE;WldS/S mice, no concurrent loss of myelinated axons was seen in the 
tibial nerve (Fig. 4A) and axons remained morphologically normal (Fig. 4B). A gross 
assessment revealed that most hindlimb muscles became extensively atrophied in 
these mice (Fig. S1B) so significantly reduced numbers of axons would have been 
expected, even in a mixed nerve such as this, if motor axon loss was the underlying 
cause. The age-dependent neuromuscular denervation in Nmnat2gtE/gtE;WldS/S 
muscles thus appears to result from selective loss of the distal ends of motor axons 
and/or their terminals. Interestingly, this mirrors the age-dependent loss of protection 
of synapses at NMJs after axotomy in homozygous WldS mice, despite continued 
protection of the main body of the transected axon (Gillingwater et al., 2002).  
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 Counts of myelinated axons in Nmnat2gtE/gtE;Sarm1-/- tibial nerves also remained 
comparable to Sarm1-/- controls even up to 24 months (Fig. 4A) with no age-related 
axon loss in either group up to this age. We also found no significant axon loss in a 
separate cohort of wild-type mice (on a related background) up to 24 months (1514 ± 
22 myelinated axons at 1.5 months compared to 1473 ± 40 at 24 months). This 
contrasts a previous study that reported significant loss of myelinated tibial nerve 
axons by 24 months in wild-type mice (Valdez et al., 2010), although this could 
simply reflect strain differences. 
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DISCUSSION 
 
To date, WldS has been the preferred tool for assessing the involvement of Wallerian-
like axon and synapse degeneration in rodent models of neurodegeneration (Conforti 
et al., 2014). However, the relatively short-term preservation of neuromuscular 
innervation by WldS in hindlimb muscles of Nmnat2gtE/gtE mice raises the possibility 
that this strategy might have greatly underestimated the involvement of Wallerian-like 
mechanisms in some models. Likely candidates are wabbler-lethal (Atp8a2wl/wl) and 
gracile axonal dystrophy (Uchl1gad/gad) mice where WldS robustly protects (proximal) 
axons but does not rescue neuromuscular symptoms (Mi et al., 2005; Zhu et al., 
2012). Human SOD1G37R, SOD1G85R and SOD1G93A transgenic mouse models of 
amyotrophic lateral sclerosis (ALS) are also candidates, although WldS largely fails to 
even protect axons in these models suggesting that unrelated degenerative 
mechanisms contribute substantially to symptoms (Vande Velde et al., 2004; Fischer 
et al., 2005). Crucially, because SARM1 deficiency confers longer-lasting 
preservation of NMJ innervation in NMNAT2-deficient mice than WldS, it could also 
confer a better outcome in these or related models. 
 We consider that prolonged preservation of Nmnat2gtE/gtE;Sarm1-/- motor axon 
terminals compared to those in Nmnat2gtE/gtE;WldS/S mice might reflect that local 
availability of WLDS, which is required for protection (Beirowski et al., 2009; Cohen et 
al., 2012), is likely to be subject to a variety of influences, whereas protection 
conferred by an absence of SARM1 will be invariant. Global expression of WLDS in 
homozygous WldS mice does not diminish significantly with age up to 12 months 
(Gillingwater et al., 2002), but we propose that normal changes in physiology, from 
as young as 2 months of age, could alter the stability, delivery or activity of WLDS in 
Nmnat2gtE/gtE;WldS/S motor axon terminals, or otherwise alter the local environment, 
such that it can no longer effectively substitute for the lack of NMNAT2 to promote 
survival. Notably, more widespread NMJ denervation in gastrocnemius compared to 
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FDB in Nmnat2gtE/gtE;WldS/S mice suggests that changes specific to different muscle 
or motor unit types are more critical to the loss of WLDS-mediated protection than 
those relating to axon length (FDB being more distal). These considerations will 
similarly apply to the age-dependent loss of protection of motor axon terminals after 
axotomy (and the resulting NMNAT2 loss) in homozygous WldS mice (Gillingwater et 
al., 2002). Interestingly, annulospiral (sensory) nerve endings in the muscle remained 
protected in older mice in that context, suggesting a motor-specific defect (Oyebode 
et al., 2012). Whilst we have also seen qualitative preservation of annulospiral 
endings in Nmnat2gtE/gtE;WldS/S FDB at 10 months (not shown), a comprehensive 
analysis of sensory innervation will be required to determine whether sensory 
endings in general are better preserved than motor axon terminals. 
 Intriguingly, a model in which sustaining the effective potency of WLDS locally is 
required for its protective effects leaves open the possibility that Sarm1 deletion may 
also be more effective than WldS at rescuing symptoms in models of other types of 
neurodegenerative disease, not just those with early neuromuscular symptoms. If the 
disease-causing defect in a given model additionally reduces the activity or 
concentration of WLDS within axons or synapses in some way, then its protective 
capacity might also be diminished. This could apply to disorders of axonal transport, 
protein synthesis or protein turnover, among others. 
Crucially, our findings have important therapeutic implications for human 
disorders. Specifically, they suggest that strategies directed at blockade of SARM1 
function have the potential to be more effective than WLDS-related therapies in 
neuromuscular synaptopathies, and potentially also in a much broader group of 
neurodegenerative disorders. In addition, the remarkable survival and health of 
Nmnat2gtE/gtE;Sarm1-/- mice into old age suggests that even long-term therapeutic 
interventions based on blocking SARM1 function might be both effective and well 
tolerated by patients. 
 11 
This study also confirms SARM1 as a key regulator of degeneration caused by a 
NMNAT2 deficiency. Remarkably, Sarm1 deletion appears to block this process 
indefinitely without affecting long-term survival, even despite the predicted 
substantial reduction in NAD-synthesizing capacity (Gilley et al., 2015). SARM1 has 
recently been shown to possess NADase activity that promotes injury-induced axon / 
synapse degeneration and which can be inhibited by NMNAT activity (Gerdts et al., 
2015; Sasaki et al., 2016; Essuman et al., 2017). Therefore, a model in which 
survival depends on NMNAT-dependent NAD production balancing NAD 
consumption, including any resulting from constitutive SARM1 NADase activity, is 
attractively simple. However, NAD consumption in uninjured Sarm1-/- axons has been 
shown to be comparable to wild-type consumption suggesting that SARM1 NADase 
activity under normal conditions is minimal (Sasaki et al., 2016). Instead, a situation 
in which a loss of NMNAT activity results in the up-regulation of SARM1 NADase 
activity via intermediate signals and/or interactions to trigger degeneration is more 
consistent with current findings (Sasaki et al., 2016; Di Stefano et al., 2017). 
 Finally, the similarity between the progressive phenotype in Nmnat2gtE/gtE;WldS/S 
mice and some mouse models of ALS is intriguing. Whilst there is, as yet, no 
established link between NMNAT2 and ALS, the SARM1 locus has been associated 
with sporadic ALS (Fogh et al., 2014) hinting at an involvement of Wallerian-like 
mechanisms. The neuromuscular defect in Nmnat2gtE/gtE;WldS/S mice could thus 
model some aspects of ALS disease pathogenesis. Even if the underlying 
mechanisms are unrelated, Nmnat2gtE/gtE;WldS/S mice would still be a useful tool for 
assessing reversibility of ALS-like symptoms as silencing of the Nmnat2gtE gene trap 
allele is conditional (Gilley et al., 2013).  
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EXPERIMENTAL PROCEDURES 
 
Mouse breeding and maintenance. 
Animal work was performed in accordance with the Animals (Scientific Procedures) 
Act, 1986, under Project License PPL 70/7620. Genotyping for the Nmnat2gtE, WldS 
and Sarm1 knockout alleles was performed as described previously (Gilley et al., 
2013; Gilley et al., 2015). Littermates were used where possible. The ages and 
genders of mice used in each individual experiment are described in Figure legends. 
 
Reverse transcriptase-PCR (RT-PCR). 
Semi-quantitative endpoint RT-PCR was used to confirm Nmnat2 gene silencing in 
the brains of Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1-/- mice aged 10-12 months 
essentially as described previously (Gilley et al., 2013).  
 
Accelerating Rotarod task. 
Locomotor performance was tested on an accelerating Rotarod (Ugo Basile, Model 
7650, Varese, Italy). Mice were familiarized with the apparatus (2x 5 min runs at 10 
rpm) one day before testing. At each test age mice performed 3x 5 min trials (3 to 30 
rpm) separated by 30 min rests. Latency to fall (max 300 seconds) was recorded. 
Only involuntary falls were scored. Mice dismounting voluntarily were placed back 
onto the apparatus once but the run was excluded from the analysis if repeated. Best 
trial performance was used for statistical analyses.  
 
Haematoxylin and eosin (H&E) staining. 
Transverse cryosections of gastrocnemius muscles snap frozen in liquid nitrogen-
chilled isopentane (8 µm thickness) or fixed in 4% paraformaldehyde (20 µm 
thickness) were stained with haematoxylin and eosin as previously described (Gilley 
et al., 2013). Images were captured using a MicroPublisher camera (QImaging) on 
 13 
an Olympus BX50 microscope (20x objective). Staining of snap-frozen muscle 
sections was optimal for visualization of muscle structure without the artefactual 
muscle fiber separation seen on fixed sections. 
 
NMJ innervation. 
Innervation of neuromuscular junctions (NMJs) in gastrocnemius and flexor digitorum 
brevis (FDB) muscles was assessed by immunofluorescent staining. Staining was 
performed essentially as described previously (Krieger et al., 2013) on whole-mount 
muscles or longitudinal cryosections (60 µm thickness). Confocal z-stack series were 
acquired using Olympus FV1000 or Leica SPE scanning laser confocal microscopes 
(20x or 40x objectives). Multiple z-stack series were acquired for each muscle and z-
projections generated for analysis. Endplate occupancy was determined by 
assessing the extent of overlap or direct abuttal of βIII-tubulin staining (axon terminal) 
with α-bungarotoxin staining (endplate). Endplates were scored as denervated when 
essentially none of the endplate (less than ~5%) was deemed occupied by the axon 
terminal, fully innervated with complete (greater than ~95%) occupancy, and partially 
innervated with intermediate occupancy (observer determined, scored blind). Original 
z-stack series were examined to exclude chance overlay of proximal axon segments 
and endplates in non-adjacent focal planes. 
 
Isometric muscle tension recordings. 
Force measurements for flexor digitorum brevis (FDB) muscle were made from FDB 
muscle-tibial nerve preparations as described previously (Beirowski et al., 2009), 
except that the proximal tendon was connected to a MLT0202 (0-25g) isometric force 
transducer (AD Instruments Ltd, Oxford, UK) and the tibial nerve was stimulated 
using 01-0.2 ms pulses of up to 10 V using a Digitimer DS2 isolated stimulator 
(Digitimer, Welwyn Garden City, UK) triggered via a Powerlab 26T interface. Tension 
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responses were digitized at 1kHz using Chart 7 or Scope 4 software (all 
ADInstruments Ltd.).  
 
Counts of myelinated tibial nerve axons. 
Transverse sections (20 µm) of fixed calf (from mid-way between knee and ankle) 
were stained with FluoroMyelin™ Red according to the manufacturer’s instructions 
(Life Technologies). Images of tibial nerves were captured on an Olympus FV1000 
point scanning confocal microscope imaging system (40x objective). Axon counts 
(inferred from numbers of myelin sheaths) were performed blind using the multi-point 
selection tool in ImageJ. 
  
Statistical analysis. 
Appropriate statistical testing of data was performed using Prism (GraphPad 
Software Inc., La Jolla, USA). Tests are described in Figure legends. A p value < 
0.05 was considered significant. 
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MAIN FIGURE TITLES & LEGENDS 
 
Figure 1. Progressive locomotor dysfunction and hindlimb muscle atrophy in 
Nmnat2gtE/gtE;WldS/S mice, but not Nmnat2gtE/gtE;Sarm1-/- mice. (A and B) Latency 
to fall in an accelerating Rotarod task for mice of the indicated genotypes and ages. 
Means ±SEM are plotted (maximum test duration 300 seconds) for n = 7/8 male mice 
of each genotype in (A) (***p <0.001 in two-way ANOVA with Dunnett's multiple 
comparisons), and n = 7 female mice each genotype in (B) (n.s. not significant [p = 
0.29] in t test). (C) Representative transverse sections of gastrocnemius muscle for 
mice of the selected genotypes and ages (as indicated) stained with haematoxylin 
and eosin. Modest fiber atrophy is seen in Nmnat2gtE/gtE;WldS/S gastrocnemius at 10 
weeks and more severe atrophy with centrally-located nuclei, hypertrophic fibers (*) 
and pyknotic nuclear clumps (arrow) are all evident at 10 months. Images are 
representative of male and female mice at 10 weeks and 8-12 months but just female 
mice at 24 months. (D and E) Gastrocnemius muscle weights for mice of the 
indicated genotypes and ages. Individual animal values with means ±SEM are 
plotted for n = 3-5 male mice per group in (D) (*p < 0.05 and ***p <0.001 in one-way 
ANOVA with Tukey's multiple comparisons, n.s. = not significant), and n = 4-5 female 
mice per group in (E) (*p < 0.05 in t test). See also Movies 1-6, Table S1 and Figure 
S1. 
 
Figure 2. Progressive loss of NMJ innervation in gastrocnemius muscles of 
Nmnat2gtE/gtE;WldS/S mice, but not Nmnat2gtE/gtE;Sarm1-/- mice. (A) Percentage of 
fully occupied (full), partially occupied (partial) and denervated endplates in 
gastrocnemius muscles from mice of the indicated genotypes and ages. Endplate 
occupancy was determined by assessing signal overlap between α-bungarotoxin 
labeling of acetylcholine receptors in the motor endplate and βIII-tubulin 
immunostaining of axon terminals (see Experimental Procedures). Total numbers of 
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NMJs analyzed in muscles from 3-5 mice per genotype (male and female) are listed 
at the base of each column. Means ±SEM of occupancy per animal are plotted (n.s. 
not significant [p > 0.05] or ***p < 0.001 in one-way ANOVA with Tukey's multiple 
comparisons of full innervation, selected comparisons). (B) Representative confocal 
z-series projections of fixed gastrocnemius (Gn) muscle preparations showing 
merged α-bungarotoxin (red) and βIII-tubulin (green) signals. Endplates in the 
images are marked as fully occupied (asterisks), partially occupied (arrows) or 
denervated (arrowheads).  
 
Figure 3. Localized loss of NMJ innervation from distinct motor unit groups in 
flexor digitorum brevis (FDB) muscle of Nmnat2gtE/gtE;WldS/S mice. (A) 
Percentage of fully occupied (full), partially occupied (partial) and denervated 
endplates in FDB muscles of 10-month-old mice of the indicated genotypes (method 
as in Fig. 2A). Total numbers of NMJs analyzed in muscles from 5-9 mice per 
genotype (male and female) are listed at the base of each column. Means ±SEM of 
occupancy per animal are plotted (n.s. not significant [p > 0.05] or **p < 0.01 in one-
way ANOVA with Tukey's multiple comparisons of full innervation, selected 
comparisons). (B) Percentage of full occupancy of endplates per imaged field 
revealed a zonal pattern of denervation in Nmnat2gtE/gtE;WldS/S FDB at 10 months with 
more widespread denervation in gastrocnemius (Gn). Fields with normal levels of full 
occupancy (80-100%) were relatively common in FDB (7/18) but absent in 
gastrocnemius (average of 16.9 and 11.6 endplates per field respectively). (C) 
Representative confocal z-series projections of fixed FDB muscle preparations 
showing merged α-bungarotoxin (red) and βIII-tubulin (green) signals highlighting 
regional variability in Nmnat2gtE/gtE;WldS/S endplate occupancy at 10 months. In 
addition to regions with widespread full occupancy (top panel) or denervation (middle 
panel), there were also areas containing degenerated endplates (bottom panel, not 
included in quantifications). (D) Isometric twitch tension recordings for representative 
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Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1-/- FDB muscle-tibial nerve preparations 
showing progressive, discrete recruitment of motor units (incremental steps in twitch 
tension) during continuously graded stimulation of the medial plantar nerve. (E) 
Motor unit numbers in FDB muscles from 10-month-old male mice of the indicated 
genotypes (n = 4 or 6 muscles from 2 or 3 mice as shown). Individual values and 
means ±SEM are plotted (n.s. not significant [p > 0.99] or ***p <0.001 in one-way 
ANOVA with Tukey's multiple comparisons, selected comparisons). See also Figure 
S2. 
 
Figure 4. No loss of myelinated tibial nerve axons in either Nmnat2gtE/gtE;WldS/S 
or Nmnat2gtE/gtE;Sarm1-/- mice. (A) Numbers of myelinated axons in tibial nerve 
(mid-calf level) from mice of the indicated genotypes and ages (WldS/S control groups 
include some Nmnat2+/gtE;WldS/S mice that were indistinguishable from WldS/S mice). 
Individual values (n = 3-8, as shown, male and female) and means ±SEM are plotted. 
No statistically significant differences were identified between groups (one-way 
ANOVA with Tukey's multiple comparisons). (B) FluoroMyelin™ Red-stained tibial 
nerve cross-sections from 10-month-old WldS/S and Nmnat2gtE/gtE;WldS/S mice 
(representative of n = 5 each genotype). No structural differences are evident even 
though Nmnat2gtE/gtE;WldS/S mice have an advanced neuromuscular defect at this 
age. 
 
 
SUPPLEMENTAL MOVIE TITLES 
 
Movie 1. 9.5-month-old female Nmnat2gtE/gtE;WldS/S mouse with advanced 
hindlimb defect. Related to Figure 1. 
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Movie 2. 8-month-old female Nmnat2gtE/gtE;WldS/S mouse with moderate 
hindlimb defect. Related to Figure 1. 
 
Movie 3. 8-month-old female Nmnat2gtE/gtE;WldS/S mouse with advanced 
hindlimb defect. Related to Figure 1. 
 
Movie 4. 8-month-old female WldS/S mouse (control). Related to Figure 1. 
 
Movie 5. 8-month-old female Nmnat2gtE/gtE;Sarm1-/- mouse. Related to Figure 1. 
 
Movie 6. 8-month-old female Sarm1-/- mouse (control). Related to Figure 1. 
 
 
 
 
 
 
 
 
Figure 1 Click here to download Figure Figure 1.tif 
Figure 2 Click here to download Figure Figure 2.tif 
Figure 3 Click here to download Figure Figure 3.tif 
Figure 4 Click here to download Figure Figure 4.tif 
 
 
 
 
Table S1. Mendelian ratios of viable offspring from Nmnat2+/gtE;WldS/S and Nmnat2+/gtE;Sarm1-/- 
crosses (updated). Related to Figure 1. 
 
 
cross 
       viable offspring (>P10) 
Genotype Obs. Exp. 
Nmnat2+/gtE;WldS/S 
x 
Nmnat2+/gtE;WldS/S 
WldS/S 67 68.5 
Nmnat2+/gtE;WldS/S 144 137 
Nmnat2gtE/gtE;WldS/S 63 68.5 
 
χ2 test p = 0.660 
 
 
 
cross 
       viable offspring (>P10) 
Genotype Obs. Exp. 
Nmnat2+/gtE;Sarm1-/- 
x 
Nmnat2+/gtE;Sarm1-/- 
Sarm1-/- 32 31.25 
Nmnat2+/gtE;Sarm1-/- 61 62.5 
Nmnat2gtE/gtE;Sarm1-/- 32 31.25 
 
χ2 test p = 0.965 
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Figure S1. Muscle atrophy and an absence of weight gain in Nmnat2gtE/gtE;WldS/S mice but not Nmnat2gtE/gtE;Sarm1-/- 
mice. Related to Figure 1. (A) RT-PCR analysis of Nmnat2 mRNA levels in brains of 10 to 12-month-old mice of the 
indicated genotypes. Actb acts as a sample reference. Images are representative of n = 3 mice per genotype. Cycle numbers 
were adjusted for Nmnat2 detection such that band intensity is close to saturation for the WldS/S and Sarm1-/- control 
samples to emphasize the relative absence of Nmnat2 mRNA in the Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1-/- samples. 
(B) Widespread hindlimb muscle wasting in Nmnat2gtE/gtE;WldS/S mice relative to matched WldS/S controls. Representative 
6-month-old female mice are shown but the phenotype invariantly develops from 3-5 months onwards in both male and 
female Nmnat2gtE/gtE;WldS/S mice. (C and D) Body weights of male and female WldS/S and Nmnat2gtE/gtE;WldS/S mice (C) and 
Sarm1-/- and Nmnat2gtE/gtE;Sarm1-/- mice (D) at the indicated ages. Individual values with means ±SEM are plotted (n.s. not 
significant [p > 0.05] or ***p <0.001 in two-way ANOVA with Bonferroni's multiple comparisons, separate tests for males 
and females).  
Nmnat2 
Actb 
Nmnat2gtE/gtE; 
WldS/S WldS/S 
Nmnat2gtE/gtE; 
Sarm1-/- Sarm1-/- 
B 
Nmnat2gtE/gtE;WldS/S WldS/S 
A 
20
 m
N
 
20
 m
N
 
400 ms 400 ms 
Nmnat2gtE/gtE;WldS/S 
10 month 
Nmnat2gtE/gtE;Sarm1-/- 
10 month 
Nmnat2gtE/gtE;WldS/S 
WldS/S 
Sarm1-/- 
am
pl
itu
de
 
stimulation 
Nmnat2gtE/gtE;Sarm1-/- 
B 
0
10
20
30
40
50
60
fa
tig
ue
 in
de
x 
0
10
20
30
40
50
60
70
80
90
m
ax
 te
ta
ni
c 
fo
rc
e 
(m
N
) 
C E D 
0 2 4 6 8
0
10
20
30
40
50
60
m
ax
 te
ta
ni
c 
fo
rc
e 
(m
N
) 
no. motor units 
Nmnat2gtE/gtE;WldS/S 
10 month 
Figure S2. Motor unit numbers are reduced in 10 month Nmnat2gtE/gtE;WldS/S FDB muscles but remaining units 
function normally. Related to Figure 2. (A) Representative maximum tetanic tension response (50 Hz stimulation for 1 
s) of FDB muscle preparations from 10-month-old male Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1-/- mice. (B) 
Maximum tetanic force of FDB muscles from10-month-old male mice of the genotypes listed. Data are mean ±SEM (n 
= 6 muscles from three mice, except for n = 4 muscles from two Sarm1-/- mice). Nmnat2gtE/gtE;WldS/S force is noticeably 
reduced compared to the other genotypes due to reduced numbers of motor units (Fig. 3E), although substantial intra-
genotype variation means that group sizes are not sufficient for statistical significance (one-way ANOVA, p > 0.05). (C) 
Correlation between (reduced) numbers of motor units in Nmnat2gtE/gtE;WldS/S FDB muscle explants and maximum 
tetanic force. Spearman correlation r = 0.986 (p = 0.0028). This suggests that, although different numbers of motor units 
remain in individual 10-month-old Nmnat2gtE/gtE;WldS/S FDB muscles, those that are present are similar in size. (D) 
Representative fatigue profiles of FDB muscle explants of the four genotypes studied (as indicated) elicited by 50 Hz 
tetanic stimulation for 3 s, at intervals of 5s (gaps between each tetanus were clipped). (E) Fatigue resistance of FDB 
muscle explants for 10-month-old mice of the genotypes listed. Individual values with means ±SEM are plotted (same 
groups sizes as in B). The index of fatigue resistance is the stimulus number that produced a tetanic force equal to 50% 
of the initial force. Fatigueability of Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1-/- FDB muscles is not significantly 
different from matched WldS/S or Sarm1-/- controls (one-way ANOVA, p > 0.05). However, grouping muscles based on 
WldS/S or Sarm1-/- status (i.e. excluding Nmnat2 status) suggests genetic background does influence fatigueability (t test 
for WldS/S and Nmnat2gtE/gtE;WldS/S versus Sarm1-/- and Nmnat2gtE/gtE;Sarm1-/-, p = 0.0126). 
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INVENTORY OF SUPPLEMENTAL INFORMATION  
 
Table S1. Mendelian ratios of viable offspring from Nmnat2+/gtE;WldS/S and Nmnat2+/gtE;Sarm1-/- 
crosses (updated). Related to Figure 1. 
Birth ratios to show that Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1-/- are born at the expected 
frequencies (updated in relation to information in the cited publications). 
 
Figure S1. Muscle atrophy and an absence of weight gain in Nmnat2gtE/gtE;WldS/S mice but not 
Nmnat2gtE/gtE;Sarm1-/- mice. Related to Figure 1. 
Additional data relating to the muscle atrophy in Nmnat2gtE/gtE;WldS/S mice. 
 
Figure S2. Motor unit numbers are reduced in 10 month Nmnat2gtE/gtE;WldS/S FDB muscles but 
remaining units function normally. Related to Figure 2. 
Data showing that motor units in Nmnat2gtE/gtE;WldS/S FDB muscles, although fewer in number, are of 
broadly equivalent size and have a fatigueability profile comparable to controls. 
 
Movies 1-6. Movies of representative 8- to 9.5-month-old female Nmnat2gtE/gtE;WldS/S (1-3), WldS/S 
(4), Nmnat2gtE/gtE;Sarm1-/- (5), and Sarm1-/- (6) and mice. Related to Figure 1. 
Movies highlighting the impaired hindlimb function in Nmnat2gtE/gtE;WldS/S mice but not 
Nmnat2gtE/gtE;Sarm1-/- mice or controls. 
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